New Interim Venous Ulcer Healing Data from enVVeno Medical VenoValve Trial to be Presented at VAM2024

enVVeno Medical Corporation (Nasdaq: NVNO) has announced that new interim data on venous ulcer healing from its VenoValve U.S. pivotal trial will be presented at the Society for Vascular Surgery 2024 Annual Meeting. The presentation by Dr. Cassius Iyad Ochoa Chaar of Yale School of Medicine is scheduled for June 21, 2024.

The data includes healing and improvement rates for patients with venous ulcers who have completed one year in the SAVVE study. Information will be shared on ulcers existing for more or less than a year prior to surgery, along with recurrence rates. Excerpts will be available on the Company's website.

Severe Chronic Venous Insufficiency (CVI) is a debilitating disease with symptoms including leg swelling, pain, and recurrent ulcers. enVVeno estimates that 2.5 million new U.S. patients annually could benefit from the VenoValve.